STOP 360: Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes
Full IRB Study Title:
Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes
IRB Study ID: 2022-175
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis that need to be treated with IV antibiotics. Do participants have the same improvement in lung function with one type of antibiotic (called beta-lactams) versus taking two different types of antibiotics (tobramycin and beta-lactams)?
Study Sponsor:
Therapeutic Development Network (TDN)
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Research Institute
(330) 543-3193
research@akronchildrens.org
Who May Qualify:
Patient 6 years and older.
Who Does NOT Qualify:
Patients with a history of lung transplant.
Lead Investigator
Debbie Toder, MD, FAAP
Medical Director, Pulmonary Function Testing Lab & Ventilator and Respiratory Technology Program; Pediatric Pulmonologist
Lewis H. Walker, MD, Cystic Fibrosis CenterPediatric Neuromuscular ClinicRobert T. Stone, MD, Respiratory Center
